Xenter is led by some of the world’s most accomplished entrepreneurs and industry veterans.



founding scientific board



From our corporate headquarters in vibrant Salt Lake City to our virtual global network, we are highly accessible and ready to connect with you.

Xenter Inc.
2463 South 3850 West
Salt Lake City, UT 84120

Xenter, Inc.
Xenter Medical Technologies
1817 Aston Avenue, Suite 105
Carlsbad, CA 92008

Xenter, Inc.
Xenter Therapeutics

440 West 13800 South
Draper, UT 84020

Richard J. Linder

Chairman & CEO
Prior to founding Xenter, Mr. Linder served as the Chairman/Chief Executive Officer of CoNextions Medical, a company he founded to specialize in the development and manufacture of medical devices for Orthopaedic Surgery in tendon re-construction and tendon to bone anchoring. Prior to CoNextions, Mr. Linder served as President of the Cardiovascular Division of Remedy Informatics, a company providing medical registries of Electronic Health Record (EHR) data. Before Remedy, Mr. Linder served as President/CEO of Coherex Medical, Inc., a Salt Lake City, UT based medical device company specializing in the development of Patent Foramen Ovale (PFO) closure devices and Left Atrial Appendage (LAA) occlusion devices for use in patients with Atrial Fibrillation (AF) and Stroke. Mr. Linder negotiated and entered into agreements with Johnson & Johnson/Biosense Webster to invest in and acquire Coherex Medical.
Prior to Coherex, Mr. Linder served as Vice President of Vascular Protection for Boston Scientific/Rubicon Medical, and he served as President/CEO of Rubicon Medical, a company he Co-Founded. Mr. Linder Co-Founded Rubicon Medical in 1996, took the company public in 2000, and invented the underlying medical devices for the Rubicon Vascular Protection Filter for patients undergoing Carotid artery and Saphenous Vein Graft stenting.
Mr. Linder began his career at Merit Medical Systems, Inc., a South Jordan, UT publicly traded (Nasdaq) global medical device company. Mr. Linder is the Founder and Chairman Emeritus of BioUtah, Utah’s independent life science association representing Utah’s medical device companies, drug development and drug discovery companies, and diagnostic companies. Mr. Linder was appointed by the Utah Speaker of the House of Representatives to the Governing Authority of the Utah Science Technology and Research Initiative (USTAR), and Mr. Linder participated in the oversight of The James L. Sorenson Molecular Biotechnology Building A USTAR Innovation Center which houses the Nano Institute of Utah, many Utah Technology Commercialization Grants, and other activities. USTAR’s Governing Authority oversaw $430M in Utah taxpayer money and assisted the University of Utah and Utah State University in recruiting world class research programs to the State of Utah’s major public universities.
Mr. Linder has served as a member of the Board of Directors for the Boy Scouts of America (Salt Lake City, UT) and was the Executive Vice President of Finance. He has served on the Board of Directors for many private and public companies including Rubicon Medical, Coherex Medical, CoNextions Medical, Juneau BioScience, Vital Access Corp., and Dynatronics. He has been an invited speaker, meeting faculty, panelist, and Keynote speaker at Transcatheter Cardiovascular Therapeutics (TCT), American College of Cardiology (ACC), Dartmouth 3D, BioUtah Life Science Summit, and many other conferences and meetings. Mr. Linder attended both Brigham Young University and the University of Utah where he studied Business Management and Organizational Behavior. Mr. Linder is the inventor of many medical devices in Interventional Cardiology, Interventional Radiology, Neuro-Interventional Radiology, Orthopedic Surgery, Female Reproductive Medicine, and a Percutaneous Left Ventricular Assist Device (LVAD). He holds more than 100 patents and patent applications in the United States for medical devices, and many more international patents. Mr. Linder has been in many countries around the world and has overseen several multi-center clinical research trials for medical devices. Mr. Linder is the recipient of the Utah Governor’s Medal for Science & Technology.

Robert Baxter

Director & EVP Business Development
Robert Baxter is a significant early investor in Xenter, has played an instrumental role in Xenter’s financing strategy and has been serving as an independent Director on the Company’s board of directors since October 2020.
While attending Utah State University, Robert founded a technology company called Arrow America Media. He is a serial entrepreneur and CEO of numerous technology, real estate and restaurant businesses. He formed a partnership with the world’s largest privately held company, Cargill, to fund real estate developers throughout the Western United States. Robert is Co-Founder/Chairman of Cypress Five Star, which owns and operates 84 Five Guys and Blaze Pizza franchises in North America.


Board Member

James R. Tobin has been at the helm of 5 different companies. Mr. Tobin is Chairman for TransMedics Group, Inc. and Chairman at TransMedics, Inc. (a subsidiary of TransMedics Group, Inc.). He has been on the board of over 20 companies, currently serving on the boards of Globus Medical, Oxford Immunotec and TransMedics.

Mr.Tobin served as President and Chief Executive Officer of Boston Scientific from March 1999 to July 2009. Before joining Boston Scientific, Mr. Tobin served as the President and CEO of Biogen, Inc., from 1997 to 1998 and as its Chief Operating Officer from 1994 to 1997. Mr. Tobin also worked at Baxter International in various capacities from 1972 to 1994, including as its President and Chief Operating Officer from 1992 to 1994. Mr. Tobin also currently serves on the board of directors of Oxford Immunotech Global PLC (NYSE: OXFD), a global diagnostics company, Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics and two private companies, TransMedics, Inc., and Resolys Bio, Inc.

He served as a Lieutenant in the U.S. Navy from 1968 to 1972. Mr. Tobin holds an M.B.A. from Harvard Business School and an A.B. from Harvard College. He is well qualified to serve on our board of directors and on our Audit Committee and Nominating and Corporate Governance Committee for numerous reasons, including his decades of experience as a senior executive of large multinational healthcare and medical device companies, and his service as a director of Boston Scientific Corporation.


Board Member

Robert S. Langer, ScD, is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. He has written more than 1,500 articles, which have been cited more than 340,000 times; his h-index of 286 is the highest of any engineer in history and tied for the 4th highest of any individual in any field. His patents have been licensed or sublicensed to more than 400 companies. He served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, and the Dreyfus Prize in Chemical Sciences. He holds 35 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.

Elazer R. Edelman, MD, PHD

Board Member/Founding Scientific Adviser
Elazer R. Edelman, M.D., Ph.D., is the Edward J. Poitras Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women’s Hospital in Boston. He and his laboratory have pioneered basic findings in vascular biology and the development and assessment of biotechnology. Dr. Edelman directs MIT’s Institute for Medical Engineering and Science (IMES) and Clinical Research Center (CRC) as well as the Harvard-MIT Biomedical Engineering Center (BMEC) – all dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease.

Dr. Edelman received Bachelor of Science degrees in Bioelectrical Engineering and in Applied Biology from MIT, a Master of Science degree in Electrical Engineering and Computer Sciences from MIT, a Ph.D. in Medical Engineering and Medical Physics from MIT, and an M.D. degree from Harvard Medical School. His graduate thesis work, under the direction of Prof. Robert Langer, defined the mathematics of regulated and controlled drug delivery systems. After internal medicine training and clinical fellowship in Cardiovascular Medicine at the BWH he spent six years as a research fellow in the Department of Pathology at Harvard Medical School with Prof. Morris J. Karnovsky working on the biology of vascular repair. Many of his findings have been or are now in clinical trial validation. More than 300 students and postdoctoral fellows have passed through Dr. Edelman’s laboratory enabling publication of more than 680 original scientific articles and some 80 patents.

Dr. Edelman is a fellow of the American College of Cardiology, the American Heart Association, the Association of University Cardiologists, the American Society of Clinical Investigation, American Institute of Medical and Biological Engineering, the American Academy of Arts and Sciences, National Academy of Inventors, the National Academy of Medicine, and the National Academy of Engineering.


Board Member

Mark Stautberg has more than 35 years of medical device Sales & Marketing experience, most notably at Boston Scientific as the Senior Vice President, Sales for the Cardiovascular businesses. As SVP from 1998-2004, he grew sales ten-fold & led the launch of the TAXUS Drug Eluting Stent to unprecedented adoption, market share, revenue & speed. During Mark’s entire fourteen plus years at Scimed/Boston Scientific, he held key roles that led to their position as the leading company in Interventional Cardiology. Prior to Boston Scientific, Mark had roles of increasing responsibility at Baxter International, including Director of Marketing for the Hospital Supply Division. He also served on numerous medical device company Boards, both private & public, where he mentored commercial teams to success. Mark has a BBA in Marketing from the University of Cincinnati.

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

David J. Bearss, Phd

Board Member/Founding Scientific Adviser

David J. Bearss, Ph.D is an experienced entrepreneur and drug developer. Dr. Bearss has a consistent and successful track record of drug discovery and development that spans the last 20 years in both academic and industrial settings. He is an expert in small molecule drug development and in the use of genetic model systems in drug discovery. He has deep experience in translational research focused on drug development and the use of genetic markers to predict drug sensitivity. Dr. Bearss has been involved in the discovery of 15 compounds that have transitioned to INDs and moved forward in clinical development. He has been a co-founder of 5 biotech companies and has been an active scientific advisor to several others. Dr. Bearss served as Chief Scientific Officer at Montigen Pharmaceuticals and SuperGen Inc. overseeing early drug discovery and development. He was the founding Co-Director of the Center for Investigational Therapeutics at the Huntsman Cancer Institute as well as an Associate Professor in the Department of Oncological Sciences at the University of Utah and Associate Professor of Physiology & Developmental Biology at Brigham Young University. Dr. Bearss was the founder and CEO of Tolero Pharmaceuticals which he led through its acquisition by Sumitomo DaiNippon Pharma in 2017. He stayed on after the acquisition as CEO of Tolero and as Global head of Research and CSO of SDP Oncology. He is also serving as the Senior Managing Director, UTAH Therapeutics Accelerator at the University of Utah which is focused on helping new therapeutic technologies discovered at the University of Utah transition to clinical development. Dr. Bearss has published more than 80 manuscripts and book chapters, has over 50 patents issued or pending and has won several awards for his scientific achievements.


Chief Financial Officer

Prior to joining Xenter, Tony served as Group Chief Financial Officer at Zimmer Biomet where he was responsible for all strategic and financial planning, business development, accounting, and internal controls for over $8B in revenues across all global business units. Additionally, Collins held numerous other financial leadership positions at Zimmer Biomet, including Vice President, Finance, Corporate Controller and Chief Accounting Officer and Vice President Finance for Global Operations and Supply Chain. Prior to Zimmer Biomet, Collins held several executive leadership positions with Guidant/Boston Scientific, including Chief Financial Officer of Guidant Japan.

Jianwei Liu

VP of Semiconductor Technology
Jianwei is a senior leader specializing in advanced sensor technologies and foundry development and operations in the semiconductor industry. His focus has been on emerging technologies on medical ultrasound imaging transducer, MEMS sensor devices, advanced chip packaging, micro-display, and magnetic disc drive.
Prior to joining Xenter, Inc. Jianwei was the VP of MEMS Technology for Butterfly Network, Inc., a Sr. Director at TDK InvenSense, and held Sr. positions at QUALCOMM, Inc., Seagate Technology and Miradia, among others.
He received his Bachelor of Science from Peking University and a Master’s degree and PhD. from the University of Michigan.


Chief Quality Officer

Scott Texley is the Lead Quality Executive for all of Xenter’s business units. His career spans over 30 years of diverse global experience within the medical/healthcare industry. During his extensive professional career, he has held various executive leadership and transformational management positions within Quality, Regulatory Compliance, Enterprise/Portfolio/Program Management and Marketing. His Medical Device experience spans a diverse set of global markets and therapies including Cardiovascular, Peripheral Interventions, Structural Heart, Neurovascular, Heart Failure, Cardiac Rhythm Management and Electrophysiology. Prior to Xenter, Mr. Texley has held Senior Vice President/Vice President/Leadership positions at Abbott Laboratories, St. Jude Medical (now Abbott), Boston Scientific Corporation and Scimed Life Systems, Inc. (now Boston Scientific).

Mr. Texley has extensive experience in formulating strategic organizational, operational and quality planning – as well as establishing world-class portfolio management systems to effectively drive product development from concept through commercialization. He also has significant experience in M&A activities – leading or assisting in the integration of Quality and Product Development systems/technologies for small, medium and large-cap medical organizations. His specific Medical Device Quality/Regulatory Compliance experience encompasses Device Class I – III, Diagnostic & Therapeutic product classifications, IDE, PMA, 510(k), HDE, Combination Products, CE-Marking within MDD 93/42/EEC, ISO 9001/ISO 13485 QMS, Certification Audits, as well as extensive global regulatory agency interactions.

Mr. Texley holds a Bachelor’s Degree in Industrial Technology/Quality Technology from the University of Wisconsin – Stout, an MBA in Leadership from the University of St. Thomas – Minnesota, and has completed numerous Executive Leadership Programs and Industry Certifications.


SVP General Manager Cardiology
Scott Heuler is President & CEO of SH Consulting Services, LLC which provides Executive Med Device Consulting Services specializing in Cardiovascular, Structural Heart, Cardiac Rhythm Management, Peripheral Vascular, Neuro Recording/Stimulation, DBS, Epilepsy, Spinal Cord Stimulation.
Mr. Heuler came to Xenter with over 25 years in sales management, marketing and senior leadership positions in the medical device industry. His background includes regional and senior sales positions with Boston Scientific Corporation in Interventional Cardiology, Structural Heart, Cardiac Rhythm Management and Peripheral Vascular. Prior to that, he was Vice President of Sales for NeuorOne Inc. Prior to that, Mr. Heuler held various senior sales and marketing roles with Guidant Corporation and U.S. Surgical Corporation.
President of Eagle Sage Capital Partners, Area Vice President of Sales for Boston Scientific and Territory Sales Manager at Guidant Corporation.
Scott received his Bachelor’s degree in Marketing/Sales Management/Finance at the University of Central Florida.


Corporate VP Regulatory Affairs
Rick Gaykowski has over 30 years of solid global experience in the medical device, combination product, regenerative medicine, and healthcare industry. During his extensive professional career, Rick has held various executive leadership and transformational management positions in Regulatory/Quality/Clinical, Compliance & Operational disciplines in a broad-range of companies (start-up – Fortune 100). Prior to Xenter, Mr. Gaykowski served as the Vice President of PolarityTE, a biologics regenerative medicine technology company, and the Vice President of Regulatory Affairs for XableCath, Inc, a specialty interventional peripheral device organization. Previously, Mr. Gaykowski served as the Vice President, Global Regulatory Affairs for Acelity/KCI/LifeCell, Inc., a world leader in advanced wound care and negative pressure wound therapy technology, and regenerative medicine tissue products. Prior to Acelity/KCI/LifeCell, Mr. Gaykowski served as Corporate Vice President, Global Regulatory, Quality, Clinical Affairs for Perseon Corporation. Before joining Perseon, Mr. Gaykowski served as Vice President, Global RA/QSystems for Lumenis, Ltd. Earlier to Lumenis, Mr. Gaykowski served as Vice President, Regulatory Affairs for Bard Access Systems, Inc., and previously held positions of Vice President, Regulatory Affairs/Quality Assurance with the Precision Vascular business unit of Boston Scientific; Precision Vascular Systems, Inc., InnerDyne, Inc., Vice President and Director of Regulatory Affairs/Quality Systems with CardioPulmonics, Inc., and Manager of Regulatory Affairs/QA/Clinical Affairs with Symbion, Inc. Mr. Gaykowski holds a Bachelor’s Degree in Behavioral Sciences & Health from the University of Utah.
Mr. Gaykowski’s product experience covers Class I – III, diagnostic & therapeutic product classifications, IDE, 510(k), de novo, PMA, HDE, combination products, 361 HCT/P, 351 biologics products, and Section 513 filings, CE-Marking in accord with MDD 93/42/EEC, ISO 9001/ISO 13485 QMS certification audits, strategic due-diligence assessments for acquisition/merger targets, and direct interaction with leading global regulatory authorities, as well as extensive experience with a variety of international Notified Bodies for QMS integration, transfer, and strategic refinement for CMDCAS and MDR certification and readiness respectively.


Executive VP & General Counsel

Mr. Pearson has a keen interest in the interplay between emerging technologies and the law. Eric’s tech hobbies include coding in Python. From 2003 to 2009, he and a partner built and sold eWatches.com, an ecommerce business specializing in wristwatches. Eric built a cryptocurrency mining rig from scratch. He most likely owns the high score for Galaga at DefCon 27’s arcade party.

Mr. Pearson has served as a founding board member of Team Kid Courage, a non-profit dedicated to helping children with disabilities, participate in sporting and other active events notwithstanding their physical limitations. Eric enjoys spending time with his wife, children and grandchildren, and is an avid skier, marathoner and mountaineer.


Director of Finance
Bret Peterson is an experienced Finance Director and MedTech Executive. Most recently, Bret was the Director of Finance at Stryker Neurovascular, the largest neurovascular medical company device company in the world, where he managed a large finance team at multiple sites throughout the United States. Prior to Stryker, he held positions as Director of Finance at Boston Scientific and Controller/Director of Finance at Precision Vascular Systems. Bret held positions at Sarcos and KPMG.
Bret received a Master’s of Management Accounting and Bachelors of Accounting from Brigham Young University.


Founding Scientific Adviser
William A. Gray, MD is the System Chief, Division of Cardiovascular Disease, at Main Line Health and President of the Lankenau Heart Institute in Philadelphia, PA. Dr. Gray graduated cum laude from Dickinson College in 1980, and Temple University School of Medicine in 1984. He completed an internship, residency, and chief residency at Brown University from 1984-88. Dr. Gray continued at Brown University until 1992, completing his clinical cardiology fellowship. Dr. Gray entered private practice in Albuquerque, NM in 1992 and continued there until 1999, during which time he was involved as a board member in the construction of a free standing Heart Hospital, served as the president of his private group, and began research in early non-surgical approaches to peripheral vascular disease, especially in patients with carotid artery disease at risk for stroke.
Dr. Gray was recruited by Swedish Medical Center in Seattle, WA to begin a program in Endovascular Care. While at Swedish, Dr. Gray began research into structural heart disease, specifically Atrial and Septal Defects, Left Atrial Appendage occlusion for patients with AF and Stroke, and Mitral Valve repair. Dr. Gray returned to academic research and joined Columbia University/New York Presbyterian Hospital from 2005-2010, and was a member of the Cardiovascular Research Foundation in New York City, NY and course Co-Director of Transcatheter Cardiovascular Therapeutics (TCT). Dr. Gray is board certified in Interventional Cardiology, Cardiovascular Disease, and Vascular Medicine.

Barry T. Katzen, MD

Founding Scientific Adviser
Barry T. Katzen, MD is Voluntary Professor of Radiology at the University of Miami School of Medicine as well as Clinical Professor of Radiology at the University of South Florida College of Medicine, and most recently became Associate Dean for Clinical Affairs at the Florida International University Herbert Wertheim College of Medicine.
Dr. Katzen received his medical degree from the University of Miami School of Medicine. He completed his radiology residency at the New York Hospital-Cornell Medical Center, with fellowship in cardiovascular radiology at St. Vincents Hospital Medical Center in New York, as well as the University of Rome, Italy. He later trained in Europe on several occasions, developing a deep understanding of the delivery of healthcare in multinational settings.
Dr. Katzen is considered a pioneer of angioplasty thrombolysis and has a particular interest in the treatment of aortic (AAA, TAA) and peripheral aneurysms, peripheral arterial disease (PAD) and critical limb ischemia, carotid artery disease, renal vascular hypertension, and vascular malformations. He has participated in the innovation of new therapies for a number of vascular diseases.
Dr. Katzen had been awarded fellowships in the American College of Cardiology, the American College of Radiology, the Society of Cardiovascular and Interventional Radiology (SIR), and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). He is one of only a few non-surgeons to be awarded membership in the Society for Vascular Surgery in the United States.
Dr. Katzen currently serves on the following advisory boards: Boston Scientific, COOK Medical, Philips Medical, Medtronic, IC Sciences, Nellix, Inc., W.L. Gore, Cordis, and CR Bard.
Dr. Katzen is a member of several societies, including the Society of Interventional Radiology, American College of Cardiology, and the American Heart Association. He is a member of the Board of Trustees for the RSNA Research and Education Foundation.
Dr. Katzen was awarded the Society of Interventional Radiology’s Gold Medal for lifetime achievement, as well as receiving the Gold Medal from the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), the first American to receive such recognition. He had also been entered into the “Hall of Fame” University of Miami School of Medicine, as well as receiving the Gold Medal from the Alumni Association.
Throughout his medical career, Dr. Katzen has been a leader in the development of new less invasive procedures and published extensively in the scientific literature. Additionally, he serves on editorial boards for numerous journals and has been the founding editor of two journals in the field. He is author and co-author of numerous text books as well. Dr. Katzen had an early interest in the use of the Internet for education and physician interaction and in 1995, along with his partners, founded the Endovascular Forum, one of the first interactive physician websites in the world.
Dr. Katzen is a program director for the International Symposium on Endovascular Therapy (ISET) and Symposium on Clinical Interventional Oncology (CIO).


Founding Scientific Adviser
Martin B. Leon, MD is Professor of Medicine at Columbia University Medical Center (CUMC). Dr. Leon is also Director of the Center for Interventional Vascular Therapy (CIVT), Director of the Cardiac Catheterization Laboratories, and on the Executive Board of the Columbia NewYork-Presbyterian Heart Valve Center. He continues as a practicing Interventional cardiologist at NewYork-Presbyterian Hospital in New York City. Dr. Leon is also the Founder and Chairman Emeritus of the Cardiovascular Research Foundation.
Dr. Leon has served as principal investigator for over 50 clinical trials that have helped shape the field of interventional cardiovascular medicine, including the following studies: STRESS, STARS, Gamma-one, SIRIUS, ENDEAVOR, and most recently, the PARTNER trial, studying the value of transcatheter valve therapy for patients with aortic stenosis. Dr. Leon has co-authored over 1550 publications, has performed over 10,000 interventional procedures, and has had a major impact as a thought-leader and innovator in the expanding sub-specialty of interventional cardiovascular device and drug therapies.
He is the Director and Founder of Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier interventional cardiovascular meeting, which recently celebrated its 24th anniversary. Dr. Leon has also served as Director or Co-Director of more than 100 international educational programs in areas of interventional cardiology. Dr. Leon has received 10 international career achievement awards and was awarded an honorary degree from the University of Athens.
Dr. Leon was previously the Director of Cardiovascular Research and Education at the Lenox Hill Heart and Vascular Institute in New York. Prior to that, he was Director of Clinical Research at the Washington Cardiology Center at the Washington Hospital Center and Clinical Professor of Medicine at Georgetown University Medical Center in Washington, DC. Earlier in his career, he served as a Clinical Associate, Senior Investigator, and Director of the Catheterization Laboratories in the Cardiology Branch of the National Heart, Lung and Blood Institute at the National Institutes of Health in Bethesda, MD. He was a founder of the Washington Cardiology Center and the Cardiology Research Foundation in Washington, DC.
Dr. Leon completed a fellowship in Cardiology at the Yale-New Haven Hospital. He completed medical school at the Yale School of Medicine, and his internship and residency in internal medicine at the Yale-New Haven Hospital.


Scientific Adviser
Dr. Ali is a board-certified cardiologist specializing in interventional and structural cardiology at St Francis Hospital and Heart Center in Roslyn, New York. He is an internationally renowned expert in complex high-risk indicated percutaneous coronary interventions (CHIP) including the treatment of chronic total occlusions (CTO) where the arteries in the heart become completely blocked.
Dr. Ali specializes in the management of cardiovascular disease in patients with pre-existing kidney disease. His research interests focus on the use of advanced imaging and physiology technologies to optimize stent implantation, with a particular interest in how these modalities protect patients from kidney injury by sparing or eliminating the need for contrast.
He has held continuous National Institute of Health (NIH) research support for over a decade.• To date, Dr Ali has published more than 200 original research and review articles in peer-reviewed journals.
Dr Ali holds investigator awards from the European Vascular Society, British Cardiovascular Society, British Atherosclerosis Society, American College of Cardiology, American Heart Association, Cardiovascular Research Foundation and European Association of Percutaneous Coronary Intervention.
He serves on the Editorial Board for three major cardiovascular journals and peer reviews regularly for over 20 journals. Dr Ali also write’s curriculum for the American College of Cardiology.
Dr Ali has been and is the Global Principal Investigator of multiple multicenter randomized trials. He developed the Resting Full-Cycle Ratio (RFR) (Abbott, Santa Clara, CA), a technology which allows interventional cardiologists to determine whether heart artery blockages warrant treatment with stents or are better served with conservative management.
He was instrumental in the development of intravascular lithotripsy (Shockwave Medical, Santa Clara, CA), a technology which uses the age-old technique of breaking kidney stones with electrical energy, to allow treatment of calcium build up in the heart arteries.
Dr Ali developed pioneering techniques to perform coronary angiography with less than a tablespoon of contrast (≈10mL) (ultra-low contrast angiography), protecting patients with advanced kidney disease from contrast associated acute kidney injury and the potential need for dialysis.
By using his expertise in intravascular imaging and physiology, he established the techniques to perform vascular interventions, including arterial stent placement, completely free of contrast administration.
Ziad Ali is the Director of the DeMatteis Cardiovascular Institute, Director of Investigational Interventional Cardiology and Director of the Cardio-renal program at St Francis Hospital and Heart Center in New York.He is Director of the Angiographic Core Laboratory at the Cardiovascular Research Foundation

Education & Training
University of Sheffield Medical School (UK)
Residency: University of Cambridge (UK)
Doctorate in Philosophy: University of Oxford (UK)
Post-doctoral Fellowship: Stanford University
Residency: Stanford University Medical Center
Fellowship: Stanford University Medical Center
Fellowship: Mount Sinai Medical Center

Honors and Awards
CRF/TCT – Best Coronary Case of TCT 2019
EuroPCR – “PCR’s got Talent” # 1 ranked scientific submission (1stof 1018)
Columbia University Louis V Gerstner Jr. Scholar
CRF/TCT Thomas J Linnemeier Spirit of Interventional Cardiology Runner-up
Best of Basic Science, American Heart Association
Northwestern Cardiovascular Young Investigator 3rd Place

Columbia University Paul Marks Scholar
American Heart Association Young Investigator
(Council on Functional Genomics and Translational Biology)
American Heart Association Peripheral Vascular Disease Award
(Council on Peripheral Vascular Disease)

Stanford Cardiovascular Medicine Outstanding Clinical Fellow Award
Stanford Cardiovascular Institute Gerald M Reaven Award (Basic Science)
Stanford Cardiovascular Institute Young Investigator Award (Basic Science)
American College of Cardiology Young Investigator Award
(Molecular and Cellular Cardiology)
British Atherosclerosis Society/British Society for Cardiovascular Research
Young Investigator Award (Basic Science)
British Cardiovascular Society Young Researcher Award (Clinical Science)
UK Vascular Society Sol Cohen (Founder’s) Young Investigator Award
William R Miller Senior Scholar– St Edmund Hall, University of Oxford
Christ Church College Senior Scholarship
Wellcome Trust Fellowship in Cardiovascular Medicine
University of Sheffield School of Medicine Valedictorian (Gold Medal)- Final MB ChB
Honors and Distinction Final MB ChB
Dr. Mark Gregory Baker (Ashby De La Zouch) Prize in Medicine and Surgery
Glaxo Wellcome Prize in Basic Clinical Sciences
Distinction Genito-urinary, Endocrine, Reproduction, Gastro-intestinal, Liver
Distinction Hematology, Immunology, Genetics, Oncology
University Overseas Scholarship for academic excellence
Ontario Scholar for academic excellence


Scientific Advisor
Richard is the Dean of the College of Engineering at the University of Utah. Professor Brown earned his Electrical Engineering Ph.D. from the University of Utah. His dissertation produced one of the first smart sensors, an array of miniature ion-selective electrodes with integrated electronics.
He started his academic career at the University of Michigan, where he developed the VLSI program and conducted research on microprocessor design, silicon-based chemical sensors, and brain probes. At Michigan he held an Arthur F. Thurnau Endowed Professorship. In 2004, he was appointed Dean of the College of Engineering at the University of Utah. The College has since grown engineering degrees granted from 484 to 1184, and research expenditures from $29M to $97M/yr. Since 2006, the College has spun out more than 76 companies.
Professor Brown has 21 patents and has authored more than 225 peer-reviewed publications. He is a founder of i-SENS (glucose sensors), Sensicore (chemical sensors), Mobius Microsystems (all-silicon clock generators), and e-SENS (water chemistry sensors). He is a Life Fellow of the IEEE and a Fellow of the National Academy of Inventors. He was awarded the Utah Governor’s Medal for Excellence in Science and Technology and was the 2018 University of Utah Rosenblatt Prize recipient.


Scientific Advisor
Dr. T. Jared Bunch, a native of Logan Utah, graduated from Utah State University with University and Department honors and received the Bill Robbins memorial award for leadership, service, and academics. He then graduated from the University of Utah School of Medicine and received Alpha Omega Alpha honors. He completed his internal medicine residency at Mayo Clinic in Rochester Minnesota. During residency he received the Outstanding Achievement Award from the Department of Medicine, the Resident Research Award from the Department of Medicine, and the Donald J. Feist Primary Care Clinic Award for Clinical Excellence. He completed fellowships in cardiovascular diseases and electrophysiology at the Mayo Clinic in Rochester Minnesota. He received the Mayo Brothers Distinguished Fellowship Award for clinical care of patients and the Donald C. Balfour Award for meritorious research. He served as an Assistant Professor of Medicine at the Mayo Clinic from 2003-2007. After fellowship he joined the cardiovascular team at Intermountain Heart Institute and directed heart rhythm research. He served as the medical director of heart rhythm services for Intermountain Healthcare. At Intermountain Medical Center he received the Physician Researcher of the Year for the Intermountain Healthcare System in 2014 and in 2017. In 2012, he was awarded a Healthcare Hero Award for Innovation by the Utah Business Association. While at Intermountain Healthcare he also was an Affiliated Clinical Associate Professor for Stanford University from 2015-2019. In 2019 he left Intermountain Healthcare to join the faculty at the University of Utah School of Medicine as a Professor of Medicine.
Dr. Bunch is active in the Heart Rhythm Society and has served as an ambassador for Central and South America and Southeast Asia. He is the founding editor of the Heart Rhythm Case Reports Journal. He is a section editor for Current Cardiology Risk Reports, Heart Rhythm Journal, and a guest editor for American Heart Journal. He is on the editorial boards of the Heart Rhythm Journal, Journal of Cardiovascular Electrophysiology, Heart, American Heart Journal, JACC electrophysiology, and the Journal of Innovations in Cardiac Rhythm Management.
Dr. Bunch specializes in the diagnosis and management of heart rhythm disorders. He performs a broad range of procedures including endocardial and epicardial catheter ablation, insertion of implantable loop recorders, pacemakers (leadless and traditional), implantable cardioverter defibrillators (ICDs – subcutaneous and traditional), and biventricular ICDs and pacemakers. He has extensive ablation experience in treatment of abnormal heart rhythms including supraventricular tachycardia, atrial fibrillation, WPW (Wolff-Parkinson-White syndrome), ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions.
Dr. Bunch is interested in the management of atrial and ventricular arrhythmias, in particular nonpharmacologic strategies such as catheter ablation and in enhancing the safety of both pharmacologic and nonpharmacologic treatments. His current research involves defining mechanisms underlying the association of atrial fibrillation and dementia and looking at therapeutic opportunities to lower risk of cognitive decline, the integration of wearable and implantable devices to improve early diagnosis and treatment of arrhythmias, and in improving mapping and catheter ablation of arrhythmias.


Scientific Advisor
James Chen-tson Fang, M.D., is the Chief of Cardiovascular Medicine at the University of Utah School of Medicine and Director of the Cardiovascular Service Line at University of Utah Health Care. He holds the John and June B. Hartman Presidential Endowed Chair and is Professor of Medicine at the University of Utah School of Medicine.
Dr. Fang graduated from Duke University with a major in Mathematics and minor in Chemistry (1984) and received his medical degree from the Duke University School of Medicine (1988). He completed his internship and residency at the Johns Hopkins Hospital (1991) and was selected as an Assistant Chief of Service (Chief Resident) for the Johns Hopkins Hospital (1993). He completed his cardiovascular (1996) and heart failure/transplant fellowships (1997) at Brigham and Women’s Hospital/Harvard Medical School.
His first faculty appointment was at the Brigham and Women’s Hospital/Harvard Medical School in 1997, where he remained until 2006. He served as Associate Professor of Medicine, Medical Director of the Heart Transplant Program as well as Program Director of the Cardiovascular Fellowship Training Program during his tenure in Boston.
In 2006, he was recruited to University Hospitals/Case Western Reserve University School of Medicine in Cleveland as Clinical Chief of Cardiovascular Medicine/Associate Chief for Clinical Affairs, Medical Director of the Heart Failure, Transplant, and Circulatory Assist Program and Chief Medical Officer for the Harrington Heart and Vascular Institute. While in Cleveland, he also held the Spitz Master Clinician Chair at Case Western Reserve University School of Medicine, where he was a Professor of Medicine.
In 2013, he assumed the role of Chief of Cardiovascular Medicine at the University of Utah and Executive Director of the UU Health’s Cardiovascular Service Line. Dr. Fang’s role at the University of Utah includes leading efforts to ensure the institution is recognized as a premier clinical, educational, and research institution for cardiovascular disease. He continues to develop highly skilled multidisciplinary teams that provide comprehensive, personalized and cost-effective care, and oversees the research, education and clinical care programs of the Cardiovascular Division.
Dr. Fang is a highly regarded clinician, teacher, mentor and researcher. He is the author of more than 175 original articles, editorials, and book chapters and has lectured nationally and internationally. He has been part of a number of important cardiovascular research groups and collaborations and has special interest in heart failure with preserved ejection fraction, advanced heart failure, coronary artery vasculopathy of the transplanted heart, and the cardiorenal syndrome. He has led several position statements for the Heart Failure Society of America as well as the International Society for Heart and Lung Transplantation. He currently serves on the ACC/AHA Heart Failure Guideline Committee and on the Board of Directors of the Heart Failure Society of America. He was elected to the Association of University Cardiologists in 2013 and is a member of the Executive Committee of the Association of Professors of Cardiology.


Scientific Advisor

William Fearon, MD graduated from Dartmouth College and received his medical degree from Columbia University College of Physicians and Surgeons, where he was elected into the Alpha Omega Alpha Medical Honor Society. He completed an Internal Medicine residency at Stanford University Medical Center serving an extra year as a Medical Chief Resident. He completed a General Cardiology and Interventional Cardiology fellowship at Stanford, spending his third year as the Chief Cardiology Fellow.  He is currently a Professor of Medicine (Cardiology) and Director on Interventional Cardiology at Stanford University School of Medicine and the Chief of the Cardiology Section at the VA Palo Alto Health Care System.  Dr. Fearon is board certified in cardiovascular medicine and interventional cardiology, and he is a fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiovascular Angiography and Interventions. He has been elected to the American Society for Clinical Investigation and the Association of University Cardiologists. 

Dr. Fearon’s primary area of research interest is in coronary physiology. He was a principal investigator for the FAME trials, which have resulted in multiple publications in the New England Journal of Medicine and led to worldwide adoption of the use of coronary physiology to guide revascularization decisions in the cardiac catheterization laboratory. He also derived and validated the index of microcirculatory resistance, which in now used commonly to assess coronary microvascular function.  He has over 250 publications, speaks regularly at major international conferences, and serves on the editorial board of the Journal of the American College of Cardiology, Circulation, JACC Cardiovascular Interventions, and Circulation: Cardiovascular Interventions, among other journals, His research laboratory has had near continuous NIH funding and he is currently the principal investigator on an NIH grant evaluating cardiac allograft vasculopathy. He has received multiple teaching awards from Stanford University and mentored numerous clinician-scientists. Dr. Fearon’s clinical activities include not only percutaneous coronary intervention, but also transcatheter aortic valve replacement. 


Scientific Advisor
David W. Grainger is a University Distinguished Professor and Department Chair of Biomedical Engineering, and Distinguished Professor of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, USA. Grainger’s research focuses on improving drug delivery methods, implanted medical device and clinical diagnostics performance, and nanomaterials toxicity. Grainger has published >210 research papers and 30 book chapters on biomaterials innovation in medicine and biotechnology, and novel surface and diagnostics chemistry (H-index 62, >14,000 citations). His research awards include a 2016 Fulbright Scholar Award (New Zealand), the 2013 Excellence in Surface Science Award (Surfaces in Biomaterials Foundation), the 2007 Clemson Award for Basic Research (Society for Biomaterials), and the 2005 American Pharmaceutical Research and Manufacturer’s Association’s award for “Excellence in Pharmaceutics”. Grainger also has received several prominent university teaching and mentoring recognitions as well as the 2019 Daniels Fund Award for Education in Research Ethics.
He has served as Chair of several prominent USA research review panels and now serves on the National Institutes of Health NIBIB Council. He serves on the editorial boards for 6 major journals, past handling editor for the journal, Biomaterials, for over two decades, and a special topics editor for Advanced Drug Delivery Reviews. He has co-organized over 30 international symposia. Dr. Grainger is recognized with numerous prominent university teaching awards and has provided nearly 400 invited lectures and outreach workshops globally. He consults widely for the biomedical device and pharmaceutical industry and has been a principal in 6 biotech start-ups, with successful commercialization efforts and marketed medtech products. Dr. Grainger continues to emphasize translational approaches to clinical biomaterials, and validation of clinical effectiveness in implants and drug delivery systems for value-based medicine. He provides leadership in official Scientific Advisory Board roles on several international medical technology research consortia and global research foundations.


Scientific Adviser
Allen Jeremias, MD, MSc is an interventional cardiologist at St. Francis Hospital, Roslyn, NY. He is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory. He is also the Director of the Physiology Core Laboratory at the Cardiovascular Research Foundation, New York, NY. He was previously the Director of the Cardiac Catheterization Laboratory at Stony Brook University Medical Center and an Associate Professor of Medicine at SUNY Stony Brook.
Dr. Jeremias earned his medical degree at Heinrich-Heine-University School of Medicine in Düsseldorf, Germany, and a Master of Science degree at Harvard Medical School. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, as well as Beth Israel Deaconess Medical Center, Harvard Medical School. Board certified in cardiovascular medicine and interventional cardiology, Dr. Jeremias is a Fellow of the American College of Cardiology as well as the Society for Cardiovascular Angiography and Interventions.
He has numerous publications in the area of interventional cardiology and is the editor of the medical text, Cardiac Intensive Care. Dr. Jeremias is the author of Your Personal Guide to Angioplasty, a patient-centered book focusing on coronary artery disease and various treatment options. He also is the recipient of numerous awards, including Castle Connolly’s Top Doctors: New York Metro Area, 2009 – 2016.


Scientific Adviser
Dr Morton J Kern, MD, is a professor of medicine at the University of California, Irvine, and chief of cardiology at the Long Beach Veterans Administration Medical Center.
Dr Kern received his medical degree and completed his internship/residency at Mount Sinai Medical Center, New York, and followed that with a fellowship at Brigham and Women’s Hospital, Boston. Before joining the University of California, Irvine, in 2006, Kern was a professor of medicine at St. Louis University, where he was also director of the J.G. Mudd Cardiac Catheterization Lab.
Kern is the author of several major textbooks, including The Cardiac Catheterization Handbook, which is used nationally and internationally to train physicians in the subject, and the recently published second edition of the SCAI Interventional Cardiology Board Review. His research interests include interventional cardiology education and practice, ACS, hemodynamics and hypertrophic cardiomyopathy

Research areas: Interventional Cardiology Education and Practice, Acute coronary syndromes, Hemodynamics, Hypertrophic Cardiomyopathy

Academic Distinctions
2014 Master, Society of Cardiac Angiography and Intervention
2013 Elite Reviewer, Journal of American College of Cardiology
2012 Elite Reviewer, Cathand Cardiovascular Intervention
2011- ‘Best Doctors in America’, peer listing US News and World Report
2010 ‘Best Doctors in America’, peer listing US News and World Report
2010 ‘Best Cardiologists in Orange County’, peer listing, OC Register
2009 Simon Dack Award, Outstanding Scholarship from the JACC
2008 Southern California ‘Super’ Doctors (Cardiology), Orange Co Mag
1993-2005 Top Doctors in St. Louis (Cardiology), St. Louis Magazine
2004 Elite Reviewer, Journal of American College of Cardiology
1989 Certificate of Proficiency, SCAI
1976 Merck Scholarship Book Award
1975 Alpha Omega Alpha Medical Honor Society

2014-Chief, Medicine Health Care Group, VA Long Beach Health Care System
2009-14 Chief, Division of Cardiology, VA Long Beach Health Care System2006- Associate Chief, Division of Cardiology, University California Irvine
2006- Professor of Medicine, Univ Calif Irvine, Orange, California
2008-2009 Director, Clinical Research, Long Beach Memorial Hospital 2005-2006 Director, Clinical Research, PCA, Costa Mesa, California
2005-2006 Voluntary Clinical Professor of Medicine, Cardiology, USC1991-2004 Professor of Medicine, St. Louis University School of Medicine1989-2004 Director, J.G. Mudd Cardiac Catheterization Lab, St. Louis Univ.1988-1991 Associate Professor of Medicine, SLU
1985-1993 Director Cardiac Cath lab, John Cochran VA , St. Louis
1985-1989 Associate Director, Cardiac Catheterization Laboratory, SLU
1985-1988 Assistant Professor of Medicine, Medicine/Cardiology, SLU
1984-1985 Associate Director, Cardiac Cath Lab. Audie L. Murphy VA UTSA
1982-1985 Assistant Professor of Medicine, Cardiology, Univ Texas HSC, San Antonio, Texas
1981-1982 Junior Associate, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA


Scientific Adviser
Dr. Mehran is currently the Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute at Mount Sinai School of Medicine and is also professor of Medicine. She sees patients for Cardiac Catheterization, Acute Coronary Syndromes, Angioplasty & Stent Placement, Clinical Trials and much more.
Additionally, Dr. Mehran is internationally recognized for her work as a clinical trial specialist with complex data analyses and outcomes research within the field of interventional cardiology and for her experience and expertise in working with regulatory agencies to conduct clinical trials. Her research interests include everything from restenosis to treatment and prevention of acute kidney injury in cardiac patients, as well as advancing treatments for acute coronary syndromes and acute myocardial infarction.


Faculty Appointment
Professor, Medicine
Mount Sinai-Icahn School of Medicine
Medical School
Grenada, 1987
Univ Conn Health Center
Internal Medicine, 1988 – 1991
Mt Sinai Hosp
Cardiovascular Disease, 1991 – 1994
Mt Sinai Hosp
Interventional Cardiology, 1994 – 1995
Board of trustees — SCAI
Program Committee for the American Heart Association Scientific Sessions
Board of directors — Harboring Hearts
Program Chair for Society of Cardiac Angiography and Interventions (SCAI- WIN (Women in Innovations)) Initiative
Chief Scientific Officer of the Clinical Trials Center at the Cardiovascular Research Foundation


Scientific Advisor
Gary Mintz, MD is the author of more than 1,000 peer-reviewed articles or book chapters and 850 abstracts concerning clinical cardiology, cardiac ultrasound, hemodynamics, coronary arteriography, interventional cardiology, and intravascular imaging and physiology. In 2005, Dr. Mintz published the single-authored textbook Intracoronary Ultrasound. He has trained more than 200 research fellows, many of whom are now key opinion leaders in their countries and internationally and is widely regarded as a “Master of Masters” in interventional cardiology.
In 2014, he received the “Master of the Masters” career achievement award and the Chien Foundation Award for Outstanding Lectureship and Lifetime Achievement at the TCTAP-Cardiovascular Summit in Seoul, Korea. He also received the Outstanding Achievement Award at CBS 2017 in Nanjing, China, and the Career Achievement Award at New Frontiers in Interventional Cardiology (NFIC) 2018 in Krakow, Poland.

Dr. Mintz completed his undergraduate education at the University of Pennsylvania in 1970 and received his medical degree from Hahnemann University in 1974, both in Philadelphia, PA. He finished his internship in 1975, residency in 1976, and cardiology fellowship in 1978, each at Hahnemann University. He joined the Hahnemann University Department of Medicine in 1978 and was promoted to Professor of Medicine in 1987 before joining CRF in 1991. His administrative appointments there included Director of the Cardiac Ultrasound Laboratory, Director of the Coronary Care Unit, and Director of the Cardiology Fellowship Training Program. He received teaching awards from both the Department of Medicine Residency and Cardiology Fellowship Training Programs.

Gus is a results driven executive with 20+ years of progressive leadership experience in advanced engineering solutions, operations management, program management and business development within growth and turnaround environments. Strategic and resourceful problem solver with demonstrated success restructuring underperforming operations, executing strategic plans, and reducing operating costs to increase profitability and productivity.
He earned a bachelor’s and master’s degree in electrical engineering from Drexel University and a bachelor’s in mathematics from Saint Vincent College.

Barry T. Katzen, MD

Scientific Advisor
Dr Moses currently serves as Director of Interventional Cardiovascular Therapeutics at Columbia University Medical Center and as Director of Advanced Cardiac Interventions at St Francis Hospital and Heart Center in Roslyn, NY. Dr. Moses is an Associate Director of the Transcatheter Cardiovascular Therapeutics (TCT) conference, the world’s largest interventional cardiology conference.
He serves on the Board of the Cardiovascular Research Foundation in New York City; and he has made important contributions in the areas of clinical research and educational activities in interventional vascular therapy. He is also a pioneer in developing approaches involving minimally invasive surgery, angioplasty, gene therapy, novel imaging technologies and various support devices that allow for wider application of interventional cardiovascular procedures.

Honors & Awards
Research Fellowship Award, Southern Pennsylvania Heart Assoc. 1978-1980
Member, PTCA Subcommittee NHLBI-Study of Thrombolysis in
Acute Myocardial Infarction (TIMI) 1986-1987
Consultant: FDA Committee on Biologics 1986
Chairman: New York Angioplasty Society 1987-1988
Lectureship, Sendai Medical College, Tohoku Medical Society,
Sendai, Japan 1990
Lectureship, The Vivian & Norman Weiden Lecture: Innovative
Approaches to Coronary Artery Disease 1996
New York Cardiological Society, NYC
Listed in Best Doctors of the Year, New York Magazine 2004-2016
America’s Top Doctors –Castle Connolly 2005-2016
Lifetime Achievement Award, Cardiovascular Research Foundation 2006
C3 Lifetime Career Achievement Award-C3 Hall of Fame 2010


Scientific Advisor
Shawn C. Owen is an Assistant Professor in Pharmaceutics and Pharmaceutical Chemistry and Adjunct Professor in the Departments of Biomedical Engineering, of Medicinal Chemistry, and of Internal Medicine at the University of Utah. He is also a member of the Huntsman Cancer Institute Experimental Therapeutics Program and the Nano Institute of Utah. Dr. Owen’s research focuses on antibody-based therapeutics and diagnostics. He is an expert on the construction and physicochemical analysis of antibody conjugates and is the co-inventor of a patented antibody-split enzyme system for diagnostic applications. He has published ~30 research papers on drug delivery and biotechnology and his research has produced 4 additional patent applications. Dr. Owen is recognized with several prominent University of Utah teaching awards and is sought for outreach workshops by both academic and industry sponsors.


Scientific Advisor
Marc Porter is a faculty member in the University of Utah’s (UofU) Department of Chemical Engineering. His research interests are in analytical chemistry, interfacial science, and nanotechnology. He is also the Director of the Nano Institute of Utah, which integrates researchers across Utah and the surrounding region into core research focus areas to address emerging “big science” questions in human health and energy. His laboratory has a long standing interest in sandwich immunoassay development and validation work using Surface-enhanced Raman Scattering (SERS) detection and giant magnetoresistance (GMR), to name a few. For over 10 years Porter also led a joint research team with personnel from NASA’s Johnson Space Center and Wyle Laboratories, a major contractor with NASA. The goal of this project was to design, construct, carry out an Earth-bound development and then microgravity flight simulations and performance assessments on a much needed water quality analyzer for eventual deployment as permanent hardware on the International Space Station (ISS). He has also co-founded several companies.


Scientific Advisor
Dr. Pinak Bipin Shah is director of the Interventional Cardiovascular Disease Training Program and director of the Cardiac Catheterization Laboratory at Brigham and Women’s Hospital (BWH). A cardiovascular medicine specialist, he is also an assistant professor of medicine at Harvard Medical School.
He received his medical degree from Perelman School of Medicine at the University of Pennsylvania. He completed an internal medicine residency at BWH and served as chief medical resident. He then completed fellowships in cardiovascular disease, interventional cardiology and cardiovascular clinical biometrics at BWH. He is board certified in cardiovascular disease and interventional cardiology.
Dr. Shah’s clinical interests include catheterization based techniques for the treatment of complex valvular and structural heart disease as well as complex coronary intervention. Dr. Shah’s practice focuses on trans-catheter aortic valve replacement (TAVR), mitral valve interventions, PFO/ASD closure, alcohol septal ablation for hypertrophic cardiomyopathy, and high-risk percutaneous coronary intervention (PCI) cases. Dr. Shah has received research funding from the Massachusetts Department of Public Health and National Heart, Lung and Blood Institute. He has also been listed one of America’s Top Doctors by Castle Connolly.


Scientific Advisor
A Fellow of the American College of Cardiology, Binoy K. Singh, MD, FACC, is a remarkable clinical cardiologist who maintains a position as Associate Chief of Cardiology at Lenox Hill Hospital/Lenox Hill Heart and Vascular at Yorktown in Yorktown Heights, New York. Dr. Singh is an entrepreneurial clinical cardiologist with biomedical engineering background and interest in healthcare system integration, new venture opportunities, physician recruitment, healthcare management and business development growth initiatives. Throughout the years, he has demonstrated success in developing new health care technical and imaging applications, clinical practice growth initiatives and developing business development opportunities. Furthermore, Dr. Singh is an Assistant Professor at Hofstra Northwell School of Medicine in Hempstead, New York, and, in the past, he was a Clinical Assistant Professor of Medicine in the Division of Cardiology at Columbia University, College of Physicians and Surgeons, Columbia University Medical Center. Dr. Singh can also be found on staff at Northwell Health Physicians Partners.


Scientific Advisor

Varinder Singh, MD, is responsible for the quality and delivery of cardiovascular care at Lenox Hill Hospital and Northwell Health’s Western Region. As chair, Dr. Singh has played an integral role in reestablishing Lenox Hill as a leading center for cardiovascular medicine in Manhattan. 

Previously, he was the director of cardiac interventions and Cath Lab operations, as well as associate director of acute coronary syndrome at Columbia University Medical Center

Dr. Singh is secretary of the Lenox Hill Medical Board and a member of the hospital’s Credentials Committee and International Services Committee. He is an assistant professor of cardiology at the Zucker School of Medicine, and his professional memberships include the American College of Cardiology, Society of Cardiovascular Angiography and Interventions, Bronx Medical Society and New York Medical Society.  

Dr. Singh, a Maryland native, completed his undergraduate education at Franklin and Marshall College. He received an MD from Meharry Medical College School of Medicine, where he was a member of the Alpha Omega Alpha Honor Medical Society. He did his residency training in internal medicine at New York Presbyterian and received the hospital’s Residents Research Award. He later completed fellowships at Drexel University College of Medicine (cardiology) and Mount Sinai Medical Center (interventional cardiology).


Scientific Advisor
Dr. Bob Sommer trained in Pediatrics and Pediatric Cardiology, and started the first Pediatric Interventional Catheterization Laboratory in New York City in 1991, and has been Board Certified in Pediatric Cardiology since 1991. In 1999, Dr. Sommer redirected his focus to the adult patient with Congenital Heart Disease, first by starting his own practice to care for this underserved population, then joining the faculty of Columbia University Medical Center in 2005. In 2017, Dr. Sommer was Board Certified in the new ABIM sub-specialty of Adult Congenital Heart Disease. Dr. Sommer performs catheter intervention for a wide array of congenital and structural disease, in “babies” of all ages including over 200 atrial septal defect, ventricular septal defect and patent foramen ovale (PFO) closures annually. Dr. Sommer was an investigator in the CLOSURE I, RESPECT and REDUCE PFO/Stroke Trials, and was the National Cardiology PI for the ESCAPE Migraine-PFO trial. He was the Co-National PI on the ASSURED Trial which led to the recent FDA approval of the Cardioform ASD Occluder. He will be the National Cardiology PI on the upcoming RELIEF Migraine-PFO Trial, based on groundbreaking research done with NP Barbara Robbins. Two manuscripts on this topic were published in the journal NEUROLOGY in November 2018. Dr. Sommer directs the Left Atrial Appendage Closure Team at Columbia, having participated in the PREVAIL Trial and the CAP2 registry using the Watchman device. He is an investigator in the Amulet and Conformal LAA device trials. He is the local PI for the COMPASSION S3 Trial, using the Edwards Sapien 3 valve in the pulmonary position. Dr. Sommer and Ms. Robbins are the primary cardiac caretakers for over 300 pediatric and adult patients with congenital heart disease, with more than 1500 office visits each year. Dr. Sommer is an Associate Professor of Medicine at Columbia University Irving Medical Center.


Scientific Adviser

Gregg W. Stone is Professor of Medicine at the Columbia University Medical Center, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital, and Co-Director of Medical Research and Education at the Cardiovascular Research Foundation in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 80 national and international multicenter randomized trials, has authored more than 2000 book chapters, manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. Dr. Stone’s areas of expertise include interventional therapies of acute coronary syndromes and myocardial infarction; drug-eluting stents; antiplatelet and antithrombotic pharmacotherapies; transcatheter mitral valve repair and replacement; new device angioplasty including atherectomy, distal embolic protection, thrombectomy, vascular brachytherapy, and stent grafts; saphenous vein graft therapies; intravascular imaging; chronic total occlusions; left atrial appendage closure; vulnerable plaque; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone, along with Dr. Martin B. Leon, is the director of Transcatheter Cardiovascular Therapeutics (TCT), the world’s largest symposium devoted to interventional cardiology and vascular medicine, directs the annual National Interventional Cardiology Fellow’s Course, and co-directs multiple other annual courses, including Optimizing Complex PCI Outcomes, The Left Main and Chronic Total Occlusion Summit, Bioresorbable Scaffolds: A Breakthrough PCI Technology, LAA Occlusion: A Technique Oriented Course, and Transcatheter Valve Therapies. Dr. Stone’s medical practice is devoted to interventional cardiology at New York-Presbyterian Hospital and Columbia University Medical Center.

Dr. Stone previously held similar positions at Lenox Hill Hospital in New York and the Washington Hospital Center in Washington, DC. Previously he was the Director of Interventional Cardiology at the Cardiovascular Institute at El Camino Hospital and Stanford University Medical Center in California.
Dr. Stone completed medical school at Johns Hopkins University Medical Center, in Baltimore, MD, and his internship and residency at the New York Hospital-Cornell Medical Center in New York City. He completed his general cardiology fellowship at Cedars-Sinai Medical Center in Los Angeles, CA, under Dr. Jeremy Swan, and subsequently a dedicated fellowship in advanced coronary angioplasty with Dr. Geoffrey O. Hartzler in Kansas City, MO.


Scientific Advisor
Dr. Tasdizen received the PhD degree in Engineering from Brown University in 2001. He is currently a Professor of Electrical and Computer Engineering and a faculty member of the Scientific Computing and Imaging (SCI) Institute at the University of Utah. His areas of expertise are image processing, biomedical image analysis and machine learning. His laboratory has been funded by the National Institutes of Health, the National Science Foundation, the Department of Energy and the Department of Homeland Security. He received the National Science Foundation’s Early CAREER award in 2012. Dr. Tasdizen’s research emphasizes developing novel solutions in image analysis and machine learning as well as making significant contributions to the driving medical applications. He has served as an Associate Editor for IEEE Transactions on Image Processing, IEEE Signal Processing Letters and BMC Bioinformatics in the past and currently continue to serve as a Senior Area Editor for IEEE Transactions on Image Processing.


Scientific Advisor
James E. Tcheng, MD is a Professor of Medicine and a Professor of Informatics at Duke University, Durham, NC. He is a practicing interventional cardiologist as well as faculty of the Duke Clinical Research Institute and the Duke Center for Health Informatics. He serves as Chief Medical Information Officer of the Duke Heart Network, Information Technology Director for the Duke Heart Center, Director of the Duke Cardiovascular Databank, and Director of Performance Improvement for the Duke Cardiology Division. He is a key investigator of the FDA Medical Device Epidemiology Network (MDEpiNet), a non-regulatory member of the International Medical Device Regulators Forum (IMDRF), past Chair of the ACC Informatics and Health IT Task Force and the ACC Digital Strategy Committee, and is a member of the ACC/AHA Task Force on Clinical Data Standards. He is on the Board of Directors of the Regenstrief Foundation and the HL7 Advisory Board and is an advisor to a number of medical innovation companies. His current work focuses on harmonizing the clinical and operational definitions and informatics of cardiovascular clinical data elements across academia, regulatory agencies, the life sciences industry, professional societies, and standards organizations, to improve the capture, communication, interoperability, and analysis of healthcare information.


Scientific Advisor
Frederick Welt, M.D. is Associate Chief of Cardiovascular Medicine at the University of Utah School of Medicine and Director of the Cardiac Catheterization Laboratory. He is a professor of medicine and member of the Interventional Cardiology faculty.
Dr. Welt most recently served as the Director of Interventional Cardiology at Brigham and Women’s Hospital in Boston, as well as Director of the Interventional Cardiovascular Experimental Laboratory. His clinical practice included outpatient clinical care and performing diagnostic catheterizations and coronary interventions.
Dr. Welt specializes in both interventional coronary and structural heart disease cases including Trans Catheter Aortic Valve Replacement (TAVR). His clinical responsibilities include invasive management of acute heart attacks and assessment of valvular heart disease, coronary stent implantation/balloon angioplasty and PFO/ASD closure.
He is also an active clinical investigator, having been involved in the PARTNER trial of transcatheter aortic valve replacement devices, translational research of novel devices to treat structural heart disease and protocols involving stem cell therapy for cardiac disease.
Dr. Welt graduated from the Yale University School of Medicine in 1992, and completed residency and fellowship at the Brigham and Women’s Hospital in Boston. He also served as Chief Resident at the West Roxbury VA Hospital and completed a research fellowship at Harvard Medical School. In addition to practicing and teaching at BWH and Harvard he has written numerous journal articles as well as serving as a reviewer for publications.